Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given a $5.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $5.00 target price on Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a report issued on Tuesday, April 2nd, Stock Target Advisor reports. The firm currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals from a hold rating to a buy rating and set a $2.75 price objective on the stock in a research report on Thursday, February 7th. ValuEngine upgraded shares of Eyepoint Pharmaceuticals from a hold rating to a buy rating in a research report on Saturday, January 5th.

Eyepoint Pharmaceuticals stock traded up $0.02 during mid-day trading on Tuesday, hitting $1.77. The company’s stock had a trading volume of 286,390 shares, compared to its average volume of 406,606. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.57 and a current ratio of 2.57. The firm has a market cap of $168.81 million, a price-to-earnings ratio of -3.05 and a beta of 1.95. Eyepoint Pharmaceuticals has a twelve month low of $1.24 and a twelve month high of $3.94.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The firm had revenue of $2.44 million for the quarter, compared to analyst estimates of $0.66 million. Eyepoint Pharmaceuticals had a negative net margin of 1,884.18% and a negative return on equity of 192.19%. As a group, equities analysts predict that Eyepoint Pharmaceuticals will post -0.32 EPS for the current fiscal year.

In related news, CEO Nancy Lurker bought 28,500 shares of the firm’s stock in a transaction on Friday, March 29th. The stock was bought at an average price of $1.76 per share, with a total value of $50,160.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Douglas Evan Godshall bought 17,000 shares of the firm’s stock in a transaction on Friday, March 29th. The shares were bought at an average cost of $1.75 per share, with a total value of $29,750.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 50,500 shares of company stock worth $89,360. Corporate insiders own 18.91% of the company’s stock.

Several large investors have recently modified their holdings of EYPT. Virtu Financial LLC acquired a new stake in shares of Eyepoint Pharmaceuticals during the 4th quarter valued at $31,000. Bank of New York Mellon Corp boosted its stake in shares of Eyepoint Pharmaceuticals by 78.5% during the 4th quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock valued at $97,000 after buying an additional 22,645 shares during the period. Regal Investment Advisors LLC boosted its stake in shares of Eyepoint Pharmaceuticals by 27.3% during the 4th quarter. Regal Investment Advisors LLC now owns 69,950 shares of the company’s stock valued at $132,000 after buying an additional 15,000 shares during the period. Private Advisor Group LLC acquired a new stake in shares of Eyepoint Pharmaceuticals during the 3rd quarter valued at $134,000. Finally, B. Riley Wealth Management Inc. acquired a new stake in shares of Eyepoint Pharmaceuticals during the 3rd quarter valued at $164,000. 57.77% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Further Reading: What is a portfolio manager?

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.